<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECT: The authors evaluated the neuroprotective effect of 5,10,15,20-tetrakis(N-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4'-pyridyl)porphyrinato-iron(III) (FeTMPyP), a <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi> decomposition catalyst, and 1,5-isoquinolinediol (ISO), a poly(<z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi> [<z:chebi fb="13" ids="16761">ADP</z:chebi>]-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase (PARP) inhibitor, alone and in combination in rats with focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Male Sprague-Dawley rats were subjected to 2 hours of MCAO followed by 22 hours of reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">Cerebral infarction</z:e> and neurological deficits were estimated after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Intraperitoneal injections of FeTMPyP (1 and 2 mg/kg) and ISO (0.05 and 0.1 mg/kg) were administered alone or in combination in ischemic animals </plain></SENT>
<SENT sid="4" pm="."><plain>The PARP activity in vehicle- and drug-treated groups was estimated using anti-poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) antibody in immunofluorescence and immunoblotting studies </plain></SENT>
<SENT sid="5" pm="."><plain>Two hours of MCAO and 22 hours of reperfusion produced significant <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and neurological deficits </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with FeTMPyP (1 and 2 mg/kg) and ISO (0.05 and 0.1 mg/kg) produced a significant reduction in <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and neurological deficits </plain></SENT>
<SENT sid="7" pm="."><plain>Combination therapy (2 mg/kg FeTMPyP and 0.1 mg/kg ISO) enhanced the inhibition of ischemic volume (77.81+/-0.86%) compared with monotherapies (FeTMPyP 54.07+/-5.6% and ISO 53.06+/-3.88%) </plain></SENT>
<SENT sid="8" pm="."><plain>Immunoblotting and immunofluorescence studies showed PARP activation after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, which was reduced by drug treatment </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Neuroprotection observed with FeTMPyP and ISO alone and in combination may be attributed to inhibition of the <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi>-PARP cascade of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion injury </plain></SENT>
</text></document>